- Home
- PLSE
as 07-26-2024 4:00pm EST
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 827.8M | IPO Year: | 2016 |
| Target Price: | N/A | AVG Volume (30 days): | 352.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.78 - $20.44 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Pulse Biosciences Inc (DE) (PLSE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Barrett Burke Thomas | PLSE | President and CEO | May 20 '24 | Buy | $8.56 | 10,000 | $85,600.00 | 10,000 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Dec 12 '23 | Buy | $9.15 | 17,999 | $164,690.85 | 36,984,179 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Dec 11 '23 | Buy | $9.36 | 90,118 | $843,504.48 | 36,966,180 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Dec 8 '23 | Buy | $9.54 | 116,656 | $1,112,898.24 | 36,876,062 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Dec 7 '23 | Buy | $9.19 | 74,852 | $687,889.88 | 36,759,406 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Dec 6 '23 | Buy | $9.06 | 82,813 | $750,285.78 | 36,684,554 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Dec 5 '23 | Buy | $9.34 | 66,021 | $616,636.14 | 351,565 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Dec 4 '23 | Buy | $10.38 | 27,000 | $280,260.00 | 285,544 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Dec 1 '23 | Buy | $9.07 | 45,600 | $413,592.00 | 258,544 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Nov 30 '23 | Buy | $9.06 | 152,944 | $1,385,672.64 | 212,944 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Nov 29 '23 | Buy | $9.44 | 158,600 | $1,497,184.00 | 36,551,461 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Nov 29 '23 | Buy | $9.21 | 60,000 | $552,600.00 | 60,000 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Nov 28 '23 | Buy | $8.98 | 124,397 | $1,117,085.06 | 36,391,194 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Nov 17 '23 | Buy | $6.10 | 241 | $1,470.10 | 36,246,797 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Nov 17 '23 | Buy | $6.09 | 10,000 | $60,900.00 | 36,256,797 | SEC Form 4 |
| DUGGAN ROBERT W | PLSE | Director10% Owner | Nov 17 '23 | Buy | $6.11 | 10,000 | $61,100.00 | 36,266,797 | SEC Form 4 |
| Levinson Mitchell E. | PLSE | Chief Strategy Officer | Nov 15 '23 | Buy | $5.88 | 3,800 | $22,344.00 | 73,027 | SEC Form 4 |
| Levinson Mitchell E. | PLSE | Chief Strategy Officer | Nov 15 '23 | Buy | $5.94 | 5,000 | $29,699.50 | 9,135 | SEC Form 4 |
| Levinson Mitchell E. | PLSE | Chief Strategy Officer | Nov 15 '23 | Buy | $5.92 | 200 | $1,184.00 | 934 | SEC Form 4 |
| Levinson Mitchell E. | PLSE | Chief Strategy Officer | Nov 15 '23 | Buy | $5.94 | 2,300 | $13,661.77 | 3,234 | SEC Form 4 |
| Levinson Mitchell E. | PLSE | Chief Strategy Officer | Nov 15 '23 | Buy | $5.94 | 100 | $594.00 | 834 | SEC Form 4 |
| Levinson Mitchell E. | PLSE | Chief Strategy Officer | Nov 15 '23 | Buy | $5.85 | 2,400 | $14,029.68 | 3,234 | SEC Form 4 |
| Levinson Mitchell E. | PLSE | Chief Strategy Officer | Nov 15 '23 | Buy | $5.90 | 100 | $590.00 | 834 | SEC Form 4 |
| Levinson Mitchell E. | PLSE | Chief Strategy Officer | Nov 15 '23 | Buy | $5.80 | 2,400 | $13,926.24 | 3,234 | SEC Form 4 |
| Levinson Mitchell E. | PLSE | Chief Strategy Officer | Nov 15 '23 | Buy | $6.13 | 1,039 | $6,372.39 | 1,039 | SEC Form 4 |
Latest Pulse Biosciences Inc (DE) News
PLSE Breaking Stock News: Dive into PLSE Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Pulse Biosciences Enters $60 Million Equity Distribution Agreement
MedTech Dive
18 days ago
Pulse drops 510(k) plan for PFA device after FDA requests clinical data
Medical Device Network
18 days ago
Pulse Biosciences receives breakthrough device status for CellFX system
MT Newswires
18 days ago
Top Midday Gainers
MT Newswires
18 days ago
Update: Pulse Biosciences Shares Jump After FDA Breakthrough Device Designation for Cardiac Surgery System
MT Newswires
18 days ago
Pulse Biosciences Receives US FDA Breakthrough Device Designation for nsPFA Cardiac Surgery System
Business Wire
18 days ago
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
Business Wire
23 days ago
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
Compare PLSE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLSE Pulse Biosciences Inc (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.